Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0065-2776(08)60455-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders.
Leuk Lymphoma
March 2019
a Division of Medical Oncology and Hematology , Princess Margaret Cancer Centre, University of Toronto, Toronto , Canada.
Soon after the anti-CD20 monoclonal antibody rituximab began to change the management of indolent and aggressive B cell lymphomas, development of alternative antibodies - including chemoimmunoconjugates - was undertaken. Among humanized and fully human CD20 antibodies, obinutuzumab has emerged as one antibody that seems to have lived up to the promise of improved efficacy based on in vitro and preclinical experiments. The data available, thus, far establish obinutuzumab's preferred role as the anti-CD20 antibody of choice in chronic lymphocytic leukemia and untreated follicular lymphoma, as well as an important addition to the treatment of rituximab-refractory indolent lymphomas.
View Article and Find Full Text PDFMonoclonal antibodies in the treatment of lung cancer.
Eur J Surg Oncol
May 2006
Department of Thoracic Surgery, Bajcsy-Zsilinszky Hospital, 89-91 Maglódi Street, Budapest 1106, Hungary.
Background: Lung cancer is an aggressive disease and its conventional therapy is far from success. There is a strong need for new, better approaches to improve survival, symptom control and quality of life.
Methods: The authors searched the literature for indexed articles published over the past 30 years from Pubmed concentrating on all possibilities of monoclonal antibodies in the therapy of tumours and especially of lung cancer.
[Application of tumor marker for immunotargeting therapy of cancer].
Nihon Rinsho
June 1996
First Department of Surgery, Kyoto Prefectural University of Medicine.
For many years, attempts have been made to utilize the monoclonal antibody against tumor markers for diagnostic purposes. On the other hand, studies with various form of immunoconjugate have demonstrated some therapeutic promise. In this paper, the ideal tumor marker for immunotargeting therapy will be discussed.
View Article and Find Full Text PDFBispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma.
Int J Cancer
May 1995
Dipartimento di Genetica, Biologia e Chimica Medica, Università di Torino, Turin, Italy.
Besides surgery, the therapeutic possibilities for the treatment of human gliomas include adoptive cellular immunotherapy, radioimmunotherapy, immunotherapy mediated by chemoimmunoconjugates and, more recently, bispecific monoclonal antibodies (biMAbs). Anti-CD3 x anti-tenascin (TN) is the first reagent of a number of biMAbs under investigation for prospective use in vivo to maximize the cell-mediated cytolytic potential of glioma patients. This biMAb originated from the fusion of 2 parental hybridomas, made resistant by retrovirus-mediated infection to the different metabolic drugs, geneticin and methotrexate, respectively.
View Article and Find Full Text PDFChemoimmunoconjugates for the treatment of cancer.
Adv Immunol
September 1994
Austin Research Institute, Austin Hospital, Victoria, Australia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!